Effects of CD30CAR+ EBV-CTLs on reactivation of CMV- or Ad-specific T-cell responses
| Donor . | Tetramers . | Tetramer+ T cells in coculture . | ||
|---|---|---|---|---|
| NT EBV-CTLs . | Irrelevant CAR+ EBV-CTLs . | CD30CAR+ EBV-CTLs . | ||
| 1 | pp65 A2 NVL | 25.7 ± 5.2 | 31.9 ± 18.1 | 27.3 ± 8.7 |
| 2 | pp65 B7 TPR | 4.0 ± 1.9 | 3.3 ± 0.6 | 5.1 ± 2.1 |
| 3 | pp65 A2 NVL | 27.3 ± 19.9 | 28.9 ± 9.6 | 33.6 ± 8.5 |
| 4 | pp65 A2 NVL | 15.6 | 22.2 | 10.9 |
| 5 | Hexon A1 TDL | 8.5 | 3.4 ± 0.6 | 3.1 ± 0.9 |
| 5 | Hexon B7 KPY | 0.2 | 0.4 ± 0.5 | 0.2 ± 0.1 |
| 6 | Hexon A24 TYF | 9.6 ± 13.2 | 1.0 ± 0.5 | 0.8 ± 0.6 |
| 7 | Hexon A1 TDL | 15.1 ± 5 | 7.9 ± 5.9 | 2.7 ± 2.8 |
| 7 | Hexon A24 TYF | 4.6 ± 2 | 3.3 ± 3.4 | 1.0 ± 0.7 |
| Donor . | Tetramers . | Tetramer+ T cells in coculture . | ||
|---|---|---|---|---|
| NT EBV-CTLs . | Irrelevant CAR+ EBV-CTLs . | CD30CAR+ EBV-CTLs . | ||
| 1 | pp65 A2 NVL | 25.7 ± 5.2 | 31.9 ± 18.1 | 27.3 ± 8.7 |
| 2 | pp65 B7 TPR | 4.0 ± 1.9 | 3.3 ± 0.6 | 5.1 ± 2.1 |
| 3 | pp65 A2 NVL | 27.3 ± 19.9 | 28.9 ± 9.6 | 33.6 ± 8.5 |
| 4 | pp65 A2 NVL | 15.6 | 22.2 | 10.9 |
| 5 | Hexon A1 TDL | 8.5 | 3.4 ± 0.6 | 3.1 ± 0.9 |
| 5 | Hexon B7 KPY | 0.2 | 0.4 ± 0.5 | 0.2 ± 0.1 |
| 6 | Hexon A24 TYF | 9.6 ± 13.2 | 1.0 ± 0.5 | 0.8 ± 0.6 |
| 7 | Hexon A1 TDL | 15.1 ± 5 | 7.9 ± 5.9 | 2.7 ± 2.8 |
| 7 | Hexon A24 TYF | 4.6 ± 2 | 3.3 ± 3.4 | 1.0 ± 0.7 |
Data are percentages of tetramer+ T cells. Coculture experiments (tetramer+ T cells in coculture with NT EBV-CTLs, irrelevant CAR+ EBV-CTLs, or CD30CAR+ EBV-CTLs) repeated 3 times for each donor, except for donor no. 4 (done only once). The tetramer used is as follows: (a) CMV peptides: HLA-A2, NLVPMVATV and HLA-B7, TPRVTGGGAM; (b) adenoviral peptides: HLA-A1, TDLGQNLLY; HLA-A24, TYFSLNNKF; HLA-B7, KPYSGTAYNSL.31
NT EBV-CTL indicates nontransduced EBV-CTLs.